Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | PNP | P00491 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | DNMT1 | P26358 | 3/20 | 0.45 |
| ▸ | ATG7 | O95352 | 2/20 | 0.45 |
| ▸ | FPR2 | P25090 | 1/20 | 0.45 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3765564 | 1.00 | AHCY (0.58) | AHCYADORA3ADORA2AHIF1ASMN1; SMN2 | |
| SCHEMBL20377688 | 0.83 | PNP (0.45) | AHCYADORA3ADORA2AHIF1ASMN1; SMN2 | |
| SCHEMBL22577509 | 0.82 | PNP (0.45) | AHCYADORA3ADORA2AHIF1ASMN1; SMN2 | |
| Deoxyadenosine SCHEMBL5182039 | 0.80 | HIF1A (0.71) | ADORA3ADORA2AHIF1ASMN1; SMN2PNP | |
| Deoxyadenosine SCHEMBL21637036 | 0.80 | HIF1A (0.71) | ADORA3ADORA2AHIF1ASMN1; SMN2PNP | |
| Deoxyadenosine SCHEMBL23982174 | 0.80 | HIF1A (0.71) | ADORA3ADORA2AHIF1ASMN1; SMN2PNP | |
| Deoxyadenosine SCHEMBL532825 | 0.80 | HIF1A (0.71) | ADORA3ADORA2AHIF1ASMN1; SMN2PNP | |
| Deoxyadenosine SCHEMBL193181 | 0.80 | HIF1A (0.71) | ADORA3ADORA2AHIF1ASMN1; SMN2PNP | |
| Deoxyadenosine SCHEMBL593935 | 0.80 | HIF1A (0.71) | ADORA3ADORA2AHIF1ASMN1; SMN2PNP | |
| Deoxyadenosine SCHEMBL19877 | 0.80 | HIF1A (0.71) | ADORA3ADORA2AHIF1ASMN1; SMN2PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2711009-A1 | Compounds for use in treating or preventing primary and metastatic breast and prostate cancer | Institut Univ. de Ciència i Tecnologia, S.A. (ES) | 2014-03-26 | — | — | EP | claimed |
| EP-2711008-A1 | N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer | Institut Univ. de Ciència i Tecnologia, S.A. (ES) | 2014-03-26 | — | — | EP | claimed |
| EP-2711007-A1 | 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer | Institut Univ. de Ciència i Tecnologia, S.A. (ES) | 2014-03-26 | — | — | EP | claimed |
| US-12584168-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-03-24 | — | — | US | disclosed |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | OPENTRONS LABWORKS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250313889-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2025-10-09 | — | — | US | disclosed |
| US-20240182906-A1 | GENOME EDITING USING EFFECTOR OLIGONUCLEOTIDES FOR THERAPEUTIC TREATMENT | Research Foundation to Cure AIDS, Inc. (US) | 2024-06-06 | — | — | US | disclosed |
| EP-4363613-A1 | DETECTING METHYLCYTOSINE USING A MODIFIED BASE OPPOSITE TO THE METHYLCYTOSINE | ILLUMINA, INC. (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20240117337-A1 | METHODS AND POLYNUCLEOTIDES FOR AMPLIFYING A TARGET POLYNUCLEOTIDE | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2024-04-11 | — | — | US | disclosed |
| US-20240076719-A9 | METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2024-03-07 | — | — | US | disclosed |
| CN-117561339-A | Detection of methylcytosine using modified bases opposite methylcytosine | 因美纳有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-20060094869-A1 | Selective process for producing an anomer of a 1-phosphorylated saccharide derivative and process for producing a nucleoside | MITSUI CHEMICALS, INC. (JP) | 2006-05-04 | — | — | US | disclosed |
| US-7038039-B2 | Process for selectively producing 1-phosphorylated sugar derivative anomer and process for producing nucleoside | MITSUI CHEMICALS, INC. (JP) | 2006-05-02 | — | — | US | disclosed |
| EP-1641942-A2 | COMBINATORIAL NUCLEOBASE OLIGOMERS COMPRISING UNIVERSAL BASE ANALOGUES AND METHODS FOR MAKING AND USING SAME | Applera Corporation (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20050053979-A1 | Combinatorial nucleobase oligomers comprising universal base analogues and methods for making and using same | APPLIED BIOSYSTEMS, LLC | 2005-03-10 | — | — | US | disclosed |
| WO-2004111072-A2 | COMBINATORIAL NUCLEOBASE OLIGOMERS COMPRISING UNIVERSAL BASE ANALOGUES AND METHODS FOR MAKING AND USING SAME | APPLERA CORPORATION (US) | 2004-12-23 | — | — | WO | disclosed |
| US-20020193314-A1 | Process for selectively producing 1-phosphorylated sugar derivative anomer and process for producing nucleoside | MITSUI CHEMICALS, INC. (JP) | 2002-12-19 | — | — | US | disclosed |
| EP-1214331-A2 | 2-AZAPURINE COMPOUNDS AND THEIR USE | Roche Diagnostics GmbH (DE) | 2002-06-19 | — | — | EP | disclosed |
| EP-1178051-A2 | PROCESS FOR SELECTIVELY PRODUCING 1-PHOSPHORYLATED SUGAR DERIVATIVE ANOMER AND PROCESS FOR PRODUCING NUCLEOSIDE | Mitsui Chemicals, Inc. (JP) | 2002-02-06 | — | — | EP | disclosed |
| WO-2001016149-A2 | 2-AZAPURINE COMPOUNDS AND THEIR USE | ROCHE DIAGNOSTICS GMBH (DE) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584168-B2 | Sample preparation method | POLN, POLRMT, POLM | AHCY 3814/4885ADORA3 1197/4885ADORA2A 1754/4885 |
| US-20060094869-A1 | Selective process for producing an anomer of a 1-phosphorylated saccharide derivative and process for producing a nucleoside | PNP, MTAP, GALE | AHCY 2247/4885ADORA3 503/4885ADORA2A 486/4885 |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | POLRMT, POLL, SARS1 | AHCY 2590/4885ADORA3 1734/4885ADORA2A 2575/4885 |
| US-20050053979-A1 | Combinatorial nucleobase oligomers comprising universal base analogues and methods for making and using same | DTYMK, UNG, TPR | AHCY 841/4885ADORA3 1671/4885ADORA2A 2400/4885 |
| US-20020193314-A1 | Process for selectively producing 1-phosphorylated sugar derivative anomer and process for producing nucleoside | PNP, GALE, MTAP | AHCY 2124/4885ADORA3 544/4885ADORA2A 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.